Full text is available at the source.
Abstract
The comparative association of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists with incident atrial fibrillation or atrial flutter remains uncertain.
- The impact of early use of SGLT2 inhibitors and GLP-1 receptor agonists on atrial fibrillation or atrial flutter is not clearly established.
- Three initial treatment strategies were compared in adults with type 2 diabetes.
- Further research may be needed to clarify the relationship between these medications and atrial fibrillation outcomes.
Simplified